A Phase 3 interventional study of BCG (50 mg) plus ANKTIVA (400 µg) and BCG (50 mg) in NMIBC, sponsored by ImmunityBio, Inc.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by ImmunityBio, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms — 6 open to participants now, 12 under way, 5 of them phase 3. BCG Vaccine · Non-Muscle Invasive Bladder Neoplasms.
Among the 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms, this one is the 17th largest by enrollment, is the only one that started in 2026, is one of 6 in phase 3, and was the 17th registered.
294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.
Browse Non-Muscle Invasive Bladder Neoplasms studies →6 of the 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Chengdu CoenBiotech Co., Ltd · Sites in China
Ages 18–75
Al-Azhar University · Sites in Egypt
ImmunityBio, Inc.
Ages 18+
By country, each count listing its studies:
BCG Vaccine: first FDA approval 1989 (N/A). What it is approved for, and how studies give it, is on its page →
Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 7 · Phase 4 2
First in 1995; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 160 across the 17 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 17 have an industry lead sponsor. The 10 most frequent:
ImmunityBio, Inc. is the lead sponsor of 83 studies on the registry; 14 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 17 (74%) have results posted.
ImmunityBio, Inc. has 8 studies filed under Non-Muscle Invasive Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06829823ImmunityBio, Inc.Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | 2026-11 |
| NCT07064863Queen's UniversityA Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. | 2027-07-31 |
| NCT04179162Memorial Sloan Kettering Cancer CenterBacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, randomized, phase 3 study of intravesical BCG plus ANKTIVA (experimental arm) versus BCG alone (control arm) in participants who have histologically confirmed, BCG-naïve/BCG-exposed high-grade Ta/T1 papillary disease. The purpose of this study is to evaluate the contribution of effect of neoadjuvant ANKTIVA plus BCG experimental therapy in papillary NMIBC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
BCG-naive disease, defined as either of the following:
Exclusion Criteria:
BCG-unresponsive disease, defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: BCG (50 mg) plus ANKTIVA (400 µg)
Biological: BCG (50 mg)
Drug pages: BCG Vaccine · Nogapendekin alfa inbakicept
First (Priming) Treatment Period: 50 mg BCG plus 400 µg ANKTIVA intravesically, weekly for 3 consecutive weeks Second (Induction) Treatment Period: 50 mg BCG plus 400 µg ANKTIVA intravesically, weekly for 6 consecutive weeks Third (Re-Induction or Maintenance) Treatment Period: 50 mg BCG plus 400 µg ANKTIVA intravesically, weekly for 6 consecutive weeks
First (Priming) Treatment Period: 50 mg BCG intravesically, weekly for 6 consecutive weeks Second (Induction) Treatment Period: Participants may be eligible for additional treatment during the second treatment period depending upon the results of the second response assessment (week 21). Third (Re-Induction or Maintenance) Treatment Period: Participants may be eligible for additional maintenance treatment during the third treatment period depending upon the results of the week 33 and subsequent response assessments, which occur every 3 months through month 6 and every 6 months thereafter through month 36.
Clinical Complete Response (CR) Rate
First response assessment, as determined by Investigator assessment of cystoscopy, cytology, and biopsy as clinically indicated
Time frame: Study Week 7
Disease Free Survival
DFS, defined as the time from randomization until recurrence of HG Ta (excluding LG Ta) disease or any grade T1 disease, new CIS, disease progression, cystectomy, change in therapy indicative of more advanced disease, or death due to any cause, whichever occurs first, regardless of re-induction.
Time frame: Approximately 36 months
No study locations are listed for this record.
Start is estimated for May 2026; primary completion for May 2032, 72 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: BCG Vaccine · Nogapendekin alfa inbakicept
Non-Muscle Invasive Bladder Neoplasms →